| Mr Donald Joseph Iasillo, RPH | |
|
125 N Main St, Concord, NH 03301-4921 | |
| (603) 224-9591 | |
| Not Available |
| Full Name | Mr Donald Joseph Iasillo |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 125 N Main St, Concord, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124112156 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | R1960 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Donald Joseph Iasillo, RPH 7 Chelsea Dr, Bow, NH 03304-5603 Ph: (603) 219-0080 | Mr Donald Joseph Iasillo, RPH 125 N Main St, Concord, NH 03301-4921 Ph: (603) 224-9591 |
News Archive
On March 17, 2010 the FDA gave approval to Envoy Medical Corporation to market a "First of its Kind" prosthetic hearing restoration device. The approval follows a December 18, 2009 unanimous 15 to 0 vote by an independent advisory panel in favor of approving the Esteem® for moderate to severe sensorineural hearing loss. The FDA chose an expedited review process, noting that they believe the Esteem® "represents a breakthrough technology."
USA Today: "Health insurance regulators in North Carolina have identified nearly $156 million in refunds owed to Blue Cross policyholders because of changes coming under the nation's new health law. Consumers with policies at other companies across the nation also may deserve refunds, says North Carolina Insurance Commissioner Wayne Goodwin. ...
Boston Scientific announces the European launch of the Precision Novi Spinal Cord Stimulator (SCS) System at the International Neuromodulation Society in Montreal, Canada. The 16-contact primary cell device has CE Mark for the treatment of chronic pain, and is the smallest high-capacity primary cell device currently available.
Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
› Verified 7 days ago
Mr. Richard Jon Tripp, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-225-2711 | |
Mr. John Michael Tracy Sr., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 38 Locke Rd, Suite 3, Concord, NH 03301 Phone: 603-223-0380 Fax: 603-223-0347 | |
Mary Kate Langlais-mcnutt, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 92 South St, Concord, NH 03301 Phone: 603-228-8400 | |
Mr. John Christopher Wakelin, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 125 N Main St, Concord, NH 03301 Phone: 603-224-9591 Fax: 603-224-5361 | |
Joseph Pirani, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Granite Pl Ste N200, Concord, NH 03301 Phone: 603-226-8686 | |
Mrs. Ann Marie Bisson, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 125 N Main St, Concord, NH 03301 Phone: 603-224-9591 | |
Mr. Khiem D Nguyen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4 Hall St, Concord, NH 03103 Phone: 603-623-3532 |